Next generation CAR T-cell therapy for cancer

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.
Picture: A/Prof Melissa Call & Prof Matt Call

Next generation CAR T-cell therapy for cancer

July 1, 2026
The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, making CAR T-cell therapy safer and more effective.
Read Transcript

The challenge

Chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient's immune cells to recognise and destroy cancer. One of the biggest challenges in CAR T-cell therapy is balancing effectiveness with safety.

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, makingCAR T-cell therapy safer and more effective. The team's research focuses on fine-tuning engineered immune cells so they remain powerful enough to destroy cancer while improving safety for patients.

The role of philanthropy

Funding from Hearts & Minds, as nominated by TDM Growth Partners, has enabled WEHI researchers to develop and test proCAR T-cells for blood and brain cancers. ProCAR T-cells are a next-generation form of CAR T-cell therapy designed to improve the precision of cancer immunotherapy, helping the body's immune system better recognise and attack cancer cells.

Unlike conventional CAR T-cells, which rely on a single signalling pathway, split proCAR technology separates these signals into two distinct circuits that can be independently adjusted. This gives researchers greater control over how the cells respond, helping them target cancer more precisely while reducing harmful side effects.

What this could unlock

The long-term goal of this research is to help patients live longer, healthier lives through safer and more effective cancer treatments.

If successful, the WEHI approach could be incorporated into CAR T-cell therapies used across a wide range of cancers and adopted by treatment centres globally. Greater confidence in how these therapies perform may also allow clinicians to consider CAR T-cell therapy earlier in a patient's treatment journey, giving more people the opportunity to benefit from this potentially life-changing approach.

For more insights into this area of research, we were fortunate to hear from Prof Matt Call from the Call Lab when he joined the Hearts & Minds podcast in 2023. You can listen below.

Funding support from Hearts & Minds, as nominated by Core Fund Manager, TDM Growth Partners. This content was last updated in July 2026, for further information visit WEHI.

The challenge

Chimeric antigen receptor (CAR) T-cell therapy involves genetically modifying a patient's immune cells to recognise and destroy cancer. One of the biggest challenges in CAR T-cell therapy is balancing effectiveness with safety.

The Call Lab at WEHI is pioneering innovative approaches to find this ‘goldilocks zone’, makingCAR T-cell therapy safer and more effective. The team's research focuses on fine-tuning engineered immune cells so they remain powerful enough to destroy cancer while improving safety for patients.

The role of philanthropy

Funding from Hearts & Minds, as nominated by TDM Growth Partners, has enabled WEHI researchers to develop and test proCAR T-cells for blood and brain cancers. ProCAR T-cells are a next-generation form of CAR T-cell therapy designed to improve the precision of cancer immunotherapy, helping the body's immune system better recognise and attack cancer cells.

Unlike conventional CAR T-cells, which rely on a single signalling pathway, split proCAR technology separates these signals into two distinct circuits that can be independently adjusted. This gives researchers greater control over how the cells respond, helping them target cancer more precisely while reducing harmful side effects.

What this could unlock

The long-term goal of this research is to help patients live longer, healthier lives through safer and more effective cancer treatments.

If successful, the WEHI approach could be incorporated into CAR T-cell therapies used across a wide range of cancers and adopted by treatment centres globally. Greater confidence in how these therapies perform may also allow clinicians to consider CAR T-cell therapy earlier in a patient's treatment journey, giving more people the opportunity to benefit from this potentially life-changing approach.

For more insights into this area of research, we were fortunate to hear from Prof Matt Call from the Call Lab when he joined the Hearts & Minds podcast in 2023. You can listen below.

Funding support from Hearts & Minds, as nominated by Core Fund Manager, TDM Growth Partners. This content was last updated in July 2026, for further information visit WEHI.

Disclaimer: This material has been prepared by Hearts & Minds, published on July 1, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Picture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale CohenPicture: Associate Professor Neale Cohen
July 1, 2026

Revolutionising Diabetes Care

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Read More
HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).HM1 Chief Operating Officer Maggie O’Neill with A/Prof Elizabeth Ng at the Murdoch Children's Research Institute in Melbourne (March 2026).
May 4, 2026

How science turned back the clock of human development to create a miracle blood stem cell

Many thought it could never be done. But three Murdoch Children’s Research Institute scientists recreated embryonic development to crack the blood stem cell code.

Read More
November 15, 2024

Professor Alex Brown in conversation with Professor Jason Kovacic

At the 2024 Sohn Hearts & Minds Conference, we heard from Professor Alex Brown in conversation with Professor Jason Kovacic about Indigenous heart health and genomics.

Read More

A/Professor Tim Sargeant | 2024 Sohn Hearts & Minds Conference

Associate Professor Tim Sargeant has been at SAHMRI (South Australian Health and Medical Research Institute) in Adelaide where he studies the role of lysosomes in Alzheimer’s disease.

Read More
July 1, 2026

Unlocking the mysteries of the human brain

The Sydney Brain Bank is helping researchers uncover the causes of neurodegenerative disease and build a future with better diagnosis, treatment and prevention.

Read More
Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.Bionics Institute researchers A/Prof Sophie Payne and Dr Tomoko Hyakumura.
July 1, 2026

A new approach to Parkinson’s Disease

Exploring nerve stimulation as a potential treatment.

Read More
Dr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds ConferenceDr Eleanor Drummond presenting at the 2025 Sohn Hearts & Minds Conference
July 1, 2026

Revealing what drives PSP

Mapping the biological changes behind progressive supranuclear palsy in the brain.

Read More
Picture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer SnaithPicture: Dr Jennifer Snaith
July 1, 2026

Advancing treatment options for type 1 diabetes

Improving blood glucose and reducing insulin needs.

Read More
July 1, 2026

Solving the genetic causes of autoimmune diseases

Mapping hundreds of risk markers to better understand how these diseases develop and progress

Read More
December 5, 2023

Prof Daniel MacArthur | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Daniel MacArthur, the Director of the Centre for Population Genomics.

Read More
December 5, 2023

Prof Michelle Simmons AO | Sohn Hearts & Minds Conference

At this year's Sohn Hearts & Minds Conference, we heard from Prof Michelle Simmons, the CEO and Founder of Silicon Quantum Computing.

Read More
December 5, 2023

Prof Misty Jenkins AO | 2023 Sohn Hearts & Minds Conference

At the 2023 Sohn Hearts & Minds Conference, we heard from Prof Misty Jenkins. Misty is a NHMRC fellow and laboratory head of the Immunology Division at the Walter and Eliza Hall Institute.

Read More
Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.Daniel MacArthur speaking at the 2023 Sohn Hearts & Minds Conference in Sydney.
November 15, 2023

Advancing Medicine Is In Daniel MacArthur’s DNA

When genomic scientist Daniel MacArthur had the opportunity to set up a new Centre for Population Genomics in Australia in 2019, he jumped at the chance to return home after 12 years living overseas.

Read More
November 10, 2023

Big thinkers in hunt for brain cancer cure

“Brain cancer is rare, but for people who do get it the prognosis is not good,” Assistant Professor Jenkins tells The Australian.

Read More
April 20, 2023

Artificial intelligence gives new hope for sufferers of severe heart problem

New AI software can improve the diagnosis of severe aortic stenosis by 72% and could potentially change the lives of about 50,000 Australians with the life-threatening condition.

Read More